Zobrazeno 1 - 10 of 73 pro vyhledávání: '"Gerald, McMahon"'
2
Data from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
Autor: Gerald McMahon, Brett S. Robinson, Sreekala Mandiyan, Yan Yang
A sound rationale exists for antibody targeting of the MET receptor tyrosine kinase, but therapeutic agents that can broadly block HGF ligand binding and exon 14–mutated or amplified MET to induce receptor degradation have yet to be reported. Here
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66076261019ae39451fda8f90daf2615
https://doi.org/10.1158/0008-5472.c.6508095.v1
Zobrazit plný text záznamu
3
Data from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
Autor: Richard Gedrich, Theresa M. LaVallee, Gerald McMahon, Andrew J. Garton, Lori Lopresti-Morrow, Linda Crew, Krista La Perle, Gerald Post, Sarah Rippy, Heather L. Gardner, Cheryl A. London
Purpose: KTN0158 is a novel anti-KIT antibody that potently inhibits wild-type and mutant KIT. This study evaluated the safety, biologic activity, and pharmacokinetic/pharmacodynamics profile of KTN0158 in dogs with spontaneous mast cell tumors (MCT)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699154d93dde439561efde9489060fb3
https://doi.org/10.1158/1078-0432.c.6526620
Zobrazit plný text záznamu
7
Supplementary Figures S1-S4 from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
Autor: Gerald McMahon, Brett S. Robinson, Sreekala Mandiyan, Yan Yang
Anti-MET antibodies demonstrated no agonistic activities in proliferation assay (S1); Sequence alignment of Sema domain β-subunit of human, monkey, canine and murine MET receptors (S2); Effect of KTN0073-IgG1, IgG2 and IgG4 antibodies on HGF-depende
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e255ed38f6b30a75f4403e806757f70
https://doi.org/10.1158/0008-5472.22410876
Zobrazit plný text záznamu
10
Akademický článek
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Autor: Diego Alvarado, Gwenda F Ligon, Jay S Lillquist, Scott B Seibel, Gerald Wallweber, Veronique M Neumeister, David L Rimm, Gerald McMahon, Theresa M LaVallee
Publikováno v: PLoS ONE, Vol 12, Iss 7, p e0181356 (2017)
Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implica
Externí odkaz: https://doaj.org/article/c695b6e9947349e89cb6ca4cd1d6440e
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje